Josep Homedes1, Marta Salichs2, Antonio Guzman3. 1. Ecuphar Veterinaria SLU (Animalcare Group) Avgda, Río de Janeiro 60 - 66 planta 13, 08016, Barcelona, Spain. jhomedes@ecuphar.es. 2. Ecuphar Veterinaria SLU (Animalcare Group) Avgda, Río de Janeiro 60 - 66 planta 13, 08016, Barcelona, Spain. 3. Welab, Barcelona Science Park (PCB), Baldiri Reixac 4-8, Edifici Clúster II, 08028, Barcelona, Spain.
Abstract
BACKGROUND: Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox® was evaluated in a target animal safety study: Groups of 4 dogs per sex each were treated once weekly with placebo or Daxocox tablets at 1-, 3- and 5-times (1X, 3X and 5X) the maximum recommended therapeutic dose of enflicoxib (0, 4, 12 or 20 mg/kg, respectively). After an initial loading dose, dogs in the placebo control, 1X and 3X groups were administered for 32 weeks, and those in the 5X group were administered for 13 weeks. Dogs were subjected to daily food consumption measurements and clinical and dose observations. Body weight measurements, physical examinations, clinical pathology, urinalysis, faecal occult blood (FOB) and electrocardiographic (ECG) and blood pressure measurements, buccal mucosal bleeding time (BMBT), ophthalmology and gastroduodenal endoscopy examinations were conducted throughout the study. At study completion, all dogs were subjected to gross necropsy. Histopathology was performed on selected tissues from all animals in all groups. RESULTS: No clinical signs were noted, and no toxicologically relevant dose-associated effects were observed. CONCLUSIONS: Results show that Daxocox® is well-tolerated and has a broad safety margin when administered as directed in dogs.
BACKGROUND:Daxocox® [Ecuphar/Animalcare Group] contains the selective COX-2 inhibitor enflicoxib, approved in the EU for the treatment of pain and inflammation associated with osteoarthritis in dogs. The safety of Daxocox® was evaluated in a target animal safety study: Groups of 4 dogs per sex each were treated once weekly with placebo or Daxocox tablets at 1-, 3- and 5-times (1X, 3X and 5X) the maximum recommended therapeutic dose of enflicoxib (0, 4, 12 or 20 mg/kg, respectively). After an initial loading dose, dogs in the placebo control, 1X and 3X groups were administered for 32 weeks, and those in the 5X group were administered for 13 weeks. Dogs were subjected to daily food consumption measurements and clinical and dose observations. Body weight measurements, physical examinations, clinical pathology, urinalysis, faecal occult blood (FOB) and electrocardiographic (ECG) and blood pressure measurements, buccal mucosal bleeding time (BMBT), ophthalmology and gastroduodenal endoscopy examinations were conducted throughout the study. At study completion, all dogs were subjected to gross necropsy. Histopathology was performed on selected tissues from all animals in all groups. RESULTS: No clinical signs were noted, and no toxicologically relevant dose-associated effects were observed. CONCLUSIONS: Results show that Daxocox® is well-tolerated and has a broad safety margin when administered as directed in dogs.
Authors: Victoria A Hampshire; Frederick M Doddy; Lynn O Post; Teresa L Koogler; Tina M Burgess; Priscilla O Batten; Roderick Hudson; Dorothy R McAdams; Margarita A Brown Journal: J Am Vet Med Assoc Date: 2004-08-15 Impact factor: 1.936
Authors: Miguel A Iñiguez; Carmen Punzón; Cristina Cacheiro-Llaguno; Manuel D Díaz-Muñoz; Javier Duque; Rosa Cuberes; Inés Alvarez; Eva M Andrés; Jordi Buxens; Helmut Buschmann; José M Vela; Manuel Fresno Journal: Int Immunopharmacol Date: 2010-08-10 Impact factor: 4.932